G. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillPodcast
![]() |
Hear G. Steven Burrill's vision of healthcare in the year 2020 in a special podcast from The Journal of Life Sciences. |
News
Biotech red hot in July as potential blockbuster M&A deals awake investors from their summer slumber August 01, 2008 | Press Release
Biotech remains upbeat in wake of market turmoil July 01, 2008 | Press Release
Genetic test industry faces tough challenges with consumers, survey finds June 17, 2008 | Press Release
See all News
Anson Fatland
Senior AssociateDr. Fatland joined Burrill & Company in July 2007 and is involved in the sourcing and development of new investment opportunities in the life sciences. Prior to joining Burrill & Company Anson spent five years working at Exelixis where he was involved in the development of the high-speed synthesis group, as well as working on multiple early stage discovery programs for the treatment of cancer. He was also the CMC leader on multiple development campaigns which are now in clinical trials for several cancer indications. Anson received his BSc in chemistry from the University of Washington, his PhD in physical organic chemistry from Washington State University, and earned a post-doctoral position in the lab of Professor Randall Halcomb at the University of Colorado, Boulder. He is currently finishing his MBA from the Haas School of Business at UC Berkeley.

.jpg)
.jpg)